Therapeutic options in the treatment of insomnia

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 9, 2005, Pages 18-23

  Erman, Milton K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; DIAZEPAM; ESTAZOLAM; FLURAZEPAM; MELATONIN; NEUROLEPTIC AGENT; QUAZEPAM; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; ZOLPIDEM; ZOPICLONE;

ANTEROGRADE AMNESIA; BEHAVIOR THERAPY; COGNITIVE THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; INSOMNIA; LIVER FAILURE; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE SUSCEPTIBILITY; SIDE EFFECT; SLEEP INDUCTION; SLEEP PATTERN; SLEEP TIME; STEVENS JOHNSON SYNDROME; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DYSSOMNIAS; HEALTH EDUCATION; HUMANS; HYPNOTICS AND SEDATIVES; PYRIDINES; RECEPTORS, MELATONIN; RELAXATION TECHNIQUES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 29444447124     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press; 2000
2. Perlis MP, McCall WV, Krystal AD, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004;65:1128-1137
3. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799
4. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM III-R primary insomnia. Hum Psychopharmacol 1998;13:191-198
5. 2 receptor agonist. Neuropharmacology 2005;48:301-310
6. Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005;6:114-121
7. Griffiths RR, Suess P. Ramelteon (TAK-375) and triazolam in humans: behavioral effects and abuse potential. In: New Research Abstracts of the 158th Annual Meeting of the American Psychiatric Association; May 25, 2005; Atlanta, Ga. Abstract NR207:76-77
8. Erman M, Seiden D, Zammit G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia. Sleep 2003;26:A298. Abstract 0748.L
9. Zammit G, Roth T, Erman M, et al. Polysomnography and outpatient study to determine the efficacy of ramelteon in adults with chronic insomnia. In: New Research Abstracts of the 158th Annual Meeting of the American Psychiatric Association; May 25, 2005; Atlanta, Ga. Abstract NR613:227
10. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized clinical trial. JAMA 1999;281:991-999
11. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001;285:1856-1864
12. Jacobs GD, Pace-Schott EF, Stickgold R, et al. Cognitive behavior therapy and pharmacotherapy for insomnia. Arch Intern Med 2004;164:1888-1896